These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12121948)

  • 21. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.
    Fishman JA; Queener SF; Roth RS; Bartlett MS
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1543-6. PubMed ID: 8395791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocystosis.
    Séguy N; Polonelli L; Dei-Cas E; Cailliez JC
    J Eukaryot Microbiol; 1997; 44(6):37S. PubMed ID: 9508425
    [No Abstract]   [Full Text] [Related]  

  • 23. Employment of terbinafine against Pneumocystis carinii infection in rat models.
    Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
    Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.
    Powles MA; Liberator P; Anderson J; Karkhanis Y; Dropinski JF; Bouffard FA; Balkovec JM; Fujioka H; Aikawa M; McFadden D; Schmatz D
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1985-9. PubMed ID: 9687394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
    Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
    J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Presence of Pneumocystis carinii and Pneumocystis wakefieldiae DNA in the extrapulmonary tissues of immunocompromised laboratory rats].
    Gołab E
    Wiad Parazytol; 2009; 55(2):167-71. PubMed ID: 19670532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.
    Hughes WT; Jacobus DP; Canfield C; Killmar J
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1417-9. PubMed ID: 8363369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
    Sun P; Tong Z
    Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.
    Merali S; Chin K; Grady RW; Clarkson AB
    Antimicrob Agents Chemother; 1996 May; 40(5):1298-300. PubMed ID: 8723489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats.
    Smith JW; Bartlett MS; Queener SF; Durkin MM; Jay MA; Hull MT; Klein RS; Marr JJ
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):113-8. PubMed ID: 3498606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Summary of the Pneumocystis research presented at the 6th International Workshop on Opportunistic Protists.
    Cushion MT
    J Eukaryot Microbiol; 1999; 46(5):85S-88S. PubMed ID: 10519261
    [No Abstract]   [Full Text] [Related]  

  • 32. Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.
    Walzer PD; Kim CK; Foy J; Zhang JL
    Antimicrob Agents Chemother; 1991 Jan; 35(1):158-63. PubMed ID: 2014971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?
    Kaneshiro ES
    Drug Resist Updat; 2001 Oct; 4(5):322-9. PubMed ID: 11991686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo models of Pneumocystis carinii.
    Bartlett MS; Queener SF; Shaw MM; Durant PJ; Lee CH; Smith JW
    J Eukaryot Microbiol; 1997; 44(6):51S. PubMed ID: 9508437
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pneumocystosis: progress in diagnosis and treatment].
    Ulewicz-Filipowicz J; Owczuk R; Schally-Kacprzak A
    Pol Merkur Lekarski; 1999 May; 6(35):286-90. PubMed ID: 10437404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.
    Bartlett MS; Edlind TD; Lee CH; Dean R; Queener SF; Shaw MM; Smith JW
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1834-7. PubMed ID: 7986016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs.
    Hall JE; Kerrigan JE; Ramachandran K; Bender BC; Stanko JP; Jones SK; Patrick DA; Tidwell RR
    Antimicrob Agents Chemother; 1998 Mar; 42(3):666-74. PubMed ID: 9517949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat.
    Brun-Pascaud M; Chau F; Derouin F; Girard PM
    Parasite; 1996 Jun; 3(2):187-9. PubMed ID: 8758556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of extrapulmonary Pneumocystis carinii in immunocompromised rats by PCR.
    Chary-Reddy S; Graves DC
    J Clin Microbiol; 1996 Jul; 34(7):1660-5. PubMed ID: 8784565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of pneumocystosis animal models: corticosteroid-treated Wistar rat; SCID mouse and nude rat.
    Aliouat EM; Martinez A; Jimenez E; Dei-Cas E; Mullet C; Delcourt P; Gargallo-Viola D
    J Eukaryot Microbiol; 1997; 44(6):41S-42S. PubMed ID: 9508429
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.